GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vera Therapeutics VERA · USD

Health Care · US listing · 🇺🇸 United States

Compare

30.61

+2.75%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2019FY2025

Net income

−$299.6m

FY2019FY2025

Free cash flow

−$241.7m

FY2019FY2025

Shareholders' equity

$604.5m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue——$1.9m————
Gross profit−$468,000−$2.2m$1.9m$846,000−$176,000−$251,000−$509,000
Research and development$215.3m$126.2m$78.2m$69.0m$22.5m$43.9m$7.3m
Operating income−$315.5m−$167.2m−$102.0m−$90.9m−$34.4m−$53.2m−$12.0m
Net income−$299.6m−$152.1m−$96.0m−$89.1m−$32.6m−$53.4m−$11.9m
Diluted earnings per share-4.66-2.77-2.16-3.20-1.53-2.61-3.46

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$734.7m$655.7m$175.5m$131.4m$83.7m$54.6m$5.4m
Cash and short-term investments$714.6m$640.9m$160.7m$114.7m$79.7m$53.7m$3.2m
Total liabilities$130.2m$78.5m$73.9m$54.5m$14.2m$143.9m$41.9m
Debt$75.4m$50.7m$49.9m$24.8m$4.9m—$100,000
Shareholders' equity$604.5m$577.2m$101.7m$76.9m$69.6m−$89.3m−$36.5m
Shares outstanding64m55m44m28m21m20m3m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$241.1m−$134.7m−$92.2m−$67.6m−$23.7m−$34.8m−$10.3m
Capital spending−$630,000−$972,000−$63,000−$62,000—−$99,000−$125,000
Free cash flow−$241.7m−$135.7m−$92.2m−$67.7m−$23.7m−$34.9m−$10.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit—−$256,000$1.1m−$564,000−$563,000———
Operating income−$112.5m−$125.1m−$94.2m−$83.9m−$80.1m−$57.2m−$48.9m−$49.8m
Net income−$109.5m−$121.0m−$91.1m−$80.3m−$76.5m−$51.7m−$43.4m−$46.6m
Diluted earnings per share-1.52-1.68-1.42-1.25-1.19-0.80-0.79-0.85
Cash from operations−$100.0m−$106.0m−$69.0m−$61.0m−$54.0m−$54.0m−$39.0m−$36.0m
Capital spending———————−$25.0m
Free cash flow———————−$61.0m
Total assets$533.0m$621.7m$734.7m$517.5m$578.5m$610.2m$655.7m$368.6m
Cash and short-term investments$499.2m$596.8m$714.6m$497.4m$556.8m$589.8m$640.9m$353.3m
Debt—$75.0m$75.4m$75.1m$75.3m$52.1m$52.2m$52.3m
Shareholders' equity$407.8m$499.7m$604.5m$398.9m$468.3m$535.0m$577.2m$289.1m

Financial ratios

Data as of 24 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin——100.0%———
Operating margin——-4951.8%———
Net margin——-5155.2%———
Return on equity-49.6%-26.4%-94.4%-115.8%-46.9%59.8%
Return on assets-40.8%-23.2%-54.7%-67.8%-38.9%-97.9%
Free cash flow yield-13.4%-8.7%-7.4%-8.7%—-6.1%
Earnings growth96.9%58.5%7.8%173.1%-38.9%350.6%
Current ratio13.64x25.67x7.71x4.91x10.73x22.55x
Debt to equity0.12x0.09x0.51x0.36x0.07x-0.00x
Equity ratio82.3%88.0%57.9%58.5%83.1%-163.8%
Interest coverage-38.78x-18.95x-24.35x-91.64x-1720.10x-320.76x
R&D as a share of sales——4201.1%———
Buybacks as a share of market value-17.0%-23.5%-59.9%-30.7%-3.9%—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income51.4%42.7%—
Net income49.8%41.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-10.9-15.3-7.1-2.1-6.2
Price to sales——367.2——

Market value over time

25 Feb 2009 to 23 Oct 2026, in USD

$3.3m$2.01bn

Share price return

Finished calendar years

20252024202320222021
Return15%159%142%-8%76%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.